Novamind strengthens its expertise in mental health and adds a communications leader


News and research before you hear about it on CNBC et al. Claim your 1-week free trial for StreetInsider Premium here.

Samantha DeLenardo Joins CAMH, Canada’s Largest Mental Health Teaching Hospital and Leader in Mental Health Research

TORONTO, ON / ACCESSWIRE / Aug 6, 2021 / Novamind Inc., (CSE: NM) (OTC PINK: NVMDF) (FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specializing in psychedelic medicine, today announced the appointment of Samantha DeLenardo as Vice President, Communications to lead communications, marketing and investor relations for Novamind.

Ms. DeLenardo has spent most of her career in the healthcare industry and has proven expertise in communicating the strategic priorities of large and complex healthcare organizations. She joins Novamind at the Center for Addiction and Mental Health (CAMH), the largest mental health teaching hospital in Canada and a leader in mental health research. During this time, she managed internal and external communications, led the successful implementation of the COVID-19 and Mental Health Online Resource Center and co-authored the hospital’s latest strategic plan with senior direction.

“At Novamind, we care deeply about the customers and the families we serve,” said DeLenardo. “We are ready to experience this transformative moment for psychedelics and mental health, in large part thanks to the courage and years of advocacy from people with lived expertise and physicians. Novamind understands both responsibility and opportunity. that await us, and I look forward to sharing the company’s story with the world. ”

Ms. DeLenardo’s experience leading high-performing teams, nurturing relationships with key stakeholders, and navigating healthcare systems and related services will be essential in supporting Novamind’s U.S. expansion strategy to clinics and research sites. She will also provide key leadership to the company’s social purpose initiatives by leveraging her humanitarian experiences as a co-founder of a national post-secondary student-athlete mental health charity.

Yaron Conforti, CEO and Director of Novamind, added: “Samantha is a strategic addition to our management team. Her unique experience gained in her senior roles at CAMH and her continued contributions to the mental health sector will be invaluable as we lead conversations and impact a wide range of stakeholders and accelerate access to mental health services through the expansion of our network of clinics. ”

About Novamind
Novamind is a leading mental health company providing secure access to psychedelic medicine through a network of clinics, retreats and clinical research sites. Novamind offers ketamine-assisted psychotherapy and other innovative treatments through its network of Cedar psychiatry clinics and operates Cedar Clinical Research, a contract research organization specializing in clinical trials and evidence-based research for psychedelic medicine. Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind improves mental wellness and guides people through their healing journey, visit

Contact details
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, Vice-President, Communications
Email: [email protected]

Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-looking statements
This press release contains forward-looking statements. All statements other than statements of historical fact included in this press release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations, including risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on forward-looking information. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release and the Company will publicly update or revise all included forward-looking statements as expressly required by applicable law.

THE SOURCE: Novamind Inc.

See the source version on

Leave A Reply

Your email address will not be published.